[HTML][HTML] Evaluation of pharmacogenetics of drug-metabolizing enzymes and drug efflux transporter in renal transplants receiving immunosuppressants
K Sridharan, S Shah, A Jassim, M Hammad… - Journal of Personalized …, 2022 - mdpi.com
Cytochrome P450 (CYP) enzymes, such as CYP3A4, and CYP3A5, P450 oxidoreductase
(POR), peroxisome proliferator activated receptor alpha (PPAR-alpha), and drug transporter …
(POR), peroxisome proliferator activated receptor alpha (PPAR-alpha), and drug transporter …
Increased hospital stay and allograft disfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285
V Bosó, MJ Herrero, S Bea, M Galiana, P Marrero… - Drug Metabolism and …, 2013 - ASPET
Pharmacogenetics correlates certain genetic variants, such as single nucleotide
polymorphisms (SNPs), with blood drug levels, efficacy, and adverse effects of the treatment …
polymorphisms (SNPs), with blood drug levels, efficacy, and adverse effects of the treatment …
[HTML][HTML] Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
S Contreras-Castillo, A Plaza, J Stojanova… - Frontiers in …, 2021 - frontiersin.org
Cyclosporine (CsA) and tacrolimus (TAC) are immunosuppressant drugs characterized by a
narrow therapeutic range and high pharmacokinetic variability. The effect of polymorphisms …
narrow therapeutic range and high pharmacokinetic variability. The effect of polymorphisms …
[PDF][PDF] Impact of CYP3A4* 1B and CYP3A5* 3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients
D ŻochowskaABCDEF, J WyzgałCDF… - Ann …, 2012 - ppm.wum.edu.pl
Summary Background: Calcineurin inhibitor (cyclosporine, CsA) and mTOR inhibitors
(sirolimus, SRL)–immunosuppressants used to prevent allograft rejection after renal …
(sirolimus, SRL)–immunosuppressants used to prevent allograft rejection after renal …
CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation
J Wang - Expert review of molecular diagnostics, 2009 - Taylor & Francis
Most immunosuppressive drugs have a narrow therapeutic index and large interpatient
variabilities in their pharmacokinetic and pharmacodynamic profiles. Identification of …
variabilities in their pharmacokinetic and pharmacodynamic profiles. Identification of …
Impact of single nucleotide polymorphisms on P450 oxidoreductase and peroxisome proliferator-activated receptor alpha on tacrolimus pharmacokinetics in renal …
S Si, Z Wang, H Yang, Z Han, J Tao, H Chen… - The …, 2019 - nature.com
The P450 oxidoreductase (POR) and peroxisome proliferator-activated receptor alpha
(PPARA) genes are associated with the activity of cytochrome P450 enzymes in vivo. We …
(PPARA) genes are associated with the activity of cytochrome P450 enzymes in vivo. We …
Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome
M Mourad, P Wallemacq, M De Meyer, J Malaise… - …, 2008 - journals.lww.com
Immunosuppressive drugs commonly used after organ transplantation to prevent acute
rejection including tacrolimus, cyclosporine, sirolimus, and mycophenolic acid are …
rejection including tacrolimus, cyclosporine, sirolimus, and mycophenolic acid are …
Genetic polymorphisms and individualized tacrolimus dosing
MALM Soria, JK Berga, SB Catalán, JM Payá… - Transplantation …, 2010 - Elsevier
BACKGROUND: Genetic polymorphisms of metabolism enzymes or intestinal drug
transporters may affect pharmacokinetic responses to immunosuppressive drugs in renal …
transporters may affect pharmacokinetic responses to immunosuppressive drugs in renal …
Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation
MJ Herrero, J Sánchez-Plumed, M Galiana… - Transplantation …, 2010 - Elsevier
Pharmacogenetics is the study of the cause of various individual responses to the same
pharmacologic therapy. Genetic alterations in a single nucleotide in the genes responsible …
pharmacologic therapy. Genetic alterations in a single nucleotide in the genes responsible …
Effect of CYP3A4* 22, CYP3A5* 3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation
D Moes, JJ Swen, J Den Hartigh… - CPT …, 2014 - Wiley Online Library
Cyclosporine, everolimus, and tacrolimus are the cornerstone of immunosuppressive
therapy in renal transplantation. These drugs are characterized by narrow therapeutic …
therapy in renal transplantation. These drugs are characterized by narrow therapeutic …